Randomised controlled clinical trial of oral etoposide versus intravenous multi-drug chemotherapy in the palliative treatment of patients with Small-Cell Lung Cancer (SCLC) and a poor prognosis

Not Applicable

Completed

• Conditions: Small-Cell Lung Cancer (SCLC); Cancer; Lung Cancer

• Registration Number: ISRCTN71172156
• Lead Sponsor: Medical Research Council (MRC) (UK)

Brief Summary

1996 results in: https://www.ncbi.nlm.nih.gov/pubmed/8774567 (added 15/11/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2002-08-19
• Study Completion: 2003-08-01
• Last Update Posted: 10 December 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 339

Inclusion Criteria

1. Microscopically proven SCLC
2. Limited or extensive disease
3. World Health Organisation (WHO) performance status grade two, three or four
4. No previous chemotherapy, radiotherapy, or surgery for small-cell lung cancer
5. No other previous or concomitant malignant disease, except basal cell carcinoma or in situ carcinoma of the cervix
6. No other serious condition contraindicating treatment with cytotoxic chemotherapy. Patients with evidence of liver cell damage are eligible
7. Renal function normal: plasma creatinine or urea concentration within normal limits
8. Plasma Billirubin less than 35 µmol/l
9. Any age, either sex

Exclusion Criteria

Not provided at time of registration.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ot provided at time of registration.

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration.